Labcorp expanded its partnership with PathAI to offer its FDA-cleared digital pathology platform at the life science giant’s U.S. network of anatomical pathology labs and participating hospitals.

Labcorp’s pathologists will use the software to review, interpret and manage digital images of slides for primary diagnosis.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx 1, an FDA-cleared digital pathology ...

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, is entering into a strategic laboratory relationship with Prisma Health, a nonprofit and the largest ...

Labcorp is now the only lab that can detect preeclampsia risk across all pregnancy trimesters "Our organization celebrates this innovative new test offering," said Eleni Tsigas, Chief Executive ...

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Toxikon, a contract research ...

Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer MRD testing helps clinicians track a patient's risk ...

(LH) on Tuesday reported fourth-quarter profit of $164.7 million. The Burlington, North Carolina-based company said it had ...

Adam Schechter, Chairman and Chief Executive Officer, and Julia Wang, Executive Vice President and Chief Financial Officer. This morning, in the Investor Relations section of our website at ...